Literature DB >> 25808163

Enteric fever and its impact on returning travellers.

Jayshree Dave1, Armine Sefton2.   

Abstract

Enteric fever, a systemic illness, is caused by Salmonella enterica serovar Typhi or S. enterica serovar Paratyphi A, B or C. The organism is transmitted to humans by the faecal oral route and is endemic in countries with poor sanitation and lacking clean drinking water. There are around 27 million individuals infected with S. Typhi worldwide annually. Enteric fever is a particular problem in travellers to endemic areas, especially those visiting friends and relatives. Currently, the two main vaccines recommended for travellers are the Vi polysaccharide vaccine and the oral Ty21a vaccine. These internationally licensed vaccines are safe and effective against S. Typhi. However, there is currently no commercially available vaccine against S. Paratyphi, which is increasingly reported as a cause of enteric fever. Vaccine uptake and taking appropriate precautions are poor in travellers visiting friends and relatives abroad; this problem requires addressing. Ciprofloxacin is no longer recommended for empirical treatment of infection because of increasing reports of resistance, especially from South Asia. Ceftriaxone and azithromycin are currently the most commonly used antimicrobials for empirical treatment of enteric fever but resistance to both these agents is emerging.
© The Author 2015. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antibiotic resistance; Enteric fever; Travellers; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 25808163     DOI: 10.1093/inthealth/ihv018

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


  4 in total

1.  The Traveller's Risk Perception (TRiP) questionnaire: pre-travel assessment and post-travel changes.

Authors:  S Tardivo; A Zenere; F Moretti; F Marchiori; D Berti; M Migliorini; A Tomasi; S Ferrari; F Tognon; G Napoletano; A Rossanese
Journal:  Int Health       Date:  2020-02-12       Impact factor: 2.473

Review 2.  Fever in travellers returning from the tropics.

Authors:  Francisco Jiménez-Morillas; Manuel Gil-Mosquera; Eric Jorge García-Lamberechts
Journal:  Med Clin (Barc)       Date:  2019-05-31       Impact factor: 1.725

Review 3.  Fever in travellers returning from the tropics.

Authors:  Francisco Jiménez-Morillas; Manuel Gil-Mosquera; Eric Jorge García-Lamberechts
Journal:  Med Clin (Engl Ed)       Date:  2019-07-27

4.  Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial.

Authors:  Amit Arjyal; Buddha Basnyat; Ho Thi Nhan; Samir Koirala; Abhishek Giri; Niva Joshi; Mila Shakya; Kamal Raj Pathak; Saruna Pathak Mahat; Shanti Pradhan Prajapati; Nabin Adhikari; Rajkumar Thapa; Laura Merson; Damodar Gajurel; Kamal Lamsal; Dinesh Lamsal; Bharat Kumar Yadav; Ganesh Shah; Poojan Shrestha; Sabina Dongol; Abhilasha Karkey; Corinne N Thompson; Nga Tran Vu Thieu; Duy Pham Thanh; Stephen Baker; Guy E Thwaites; Marcel Wolbers; Christiane Dolecek
Journal:  Lancet Infect Dis       Date:  2016-01-20       Impact factor: 71.421

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.